S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Soligenix Stock Forecast, Price & News

+0.03 (+3.46%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
268,212 shs
Average Volume
2.00 million shs
Market Capitalization
$36.01 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

Soligenix logo

About Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.


SNGX: Durable Immunity for RiVax® Vaccine…
November 22, 2021 |  finance.yahoo.com
Soligenix (NASDAQ:SNGX) Announces Earnings Results
November 13, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$2.36 million
Book Value
$0.12 per share


Net Income
$-17.69 million
Net Margins
Pretax Margin




Free Float
Market Cap
$36.01 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

1.64 out of 5 stars

Medical Sector

989th out of 1,391 stocks

Pharmaceutical Preparations Industry

468th out of 669 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Soligenix (NASDAQ:SNGX) Frequently Asked Questions

Is Soligenix a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Soligenix stock.
View analyst ratings for Soligenix
or view top-rated stocks.

How has Soligenix's stock been impacted by COVID-19?

Soligenix's stock was trading at $2.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SNGX shares have decreased by 64.6% and is now trading at $0.8980.
View which stocks have been most impacted by COVID-19

When is Soligenix's next earnings date?

Soligenix is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Soligenix

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) issued its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.03. Soligenix had a negative trailing twelve-month return on equity of 105.58% and a negative net margin of 945.53%.
View Soligenix's earnings history

What price target have analysts set for SNGX?

2 brokers have issued 12-month target prices for Soligenix's stock. Their forecasts range from $1.50 to $3.75. On average, they anticipate Soligenix's share price to reach $2.63 in the next year. This suggests a possible upside of 192.3% from the stock's current price.
View analysts' price targets for Soligenix
or view top-rated stocks among Wall Street analysts.

Who are Soligenix's key executives?

Soligenix's management team includes the following people:
  • Christopher J. Schaber, Chairman, President & Chief Executive Officer
  • Jonathan L. Guarino, Chief Financial Officer, Secretary & Senior VP
  • Oreola Donini, Chief Scientific Officer & Senior Vice President
  • Richard C. Straube, Chief Medical Officer & Senior Vice President
  • Adam T. Rumage, VP-Regulatory Affairs & Project Management

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

Who are Soligenix's major shareholders?

Soligenix's stock is owned by many different institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.75%), Citadel Advisors LLC (0.54%), BlackRock Inc. (0.29%), Two Sigma Securities LLC (0.15%) and Millennium Management LLC (0.07%).
View institutional ownership trends for Soligenix

Which institutional investors are selling Soligenix stock?

SNGX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Soligenix
or view top insider-selling stocks.

Which institutional investors are buying Soligenix stock?

SNGX stock was bought by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Two Sigma Securities LLC, Geode Capital Management LLC, and Millennium Management LLC.
View insider buying and selling activity for Soligenix
or or view top insider-buying stocks.

How do I buy shares of Soligenix?

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $0.90.

How much money does Soligenix make?

Soligenix has a market capitalization of $36.01 million and generates $2.36 million in revenue each year. The biopharmaceutical company earns $-17.69 million in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Soligenix have?

Soligenix employs 18 workers across the globe.

When was Soligenix founded?

Soligenix was founded in 1987.

What is Soligenix's official website?

The official website for Soligenix is www.soligenix.com.

Where are Soligenix's headquarters?

Soligenix is headquartered at 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at (609) 538-8200, via email at [email protected], or via fax at 609-452-6467.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.